Britain and America have forged a significant commercial pact that will maintain no import taxes on British medicine exports entering the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost spending on medicines through the National Health Service (NHS). This pledge secures that duties on these crucial goods will remain at zero for a timeframe of three years.
This deal comes after previous threats to significantly raise import taxes on patented drug imports, with potential rates floated reaching 100%.
"This arrangement between the Britain reinforces the global environment for innovative medicines and introduces long-overdue fairness to U.S.–U.K. pharmaceutical trade," a statement said.
Commercial Impact
Pharmaceuticals represent one of the the United Kingdom's largest exports to the America, which is clearly the biggest market for leading companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period prior to last September, the UK exported pharmaceutical products totaling £11.1bn to the US. This value accounted for nearly one-fifth of total UK exports in that period.
"This guarantee secures employment, stimulates investment and paves the way for the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.
Detailed NHS Changes
The pact involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a goal to raise overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. Last year, refunds exceeded 20%.
Broader Context
The pact follows a ongoing row between the drug companies and the UK government over medicine costs and regulatory access.
The disagreement were intensified by arguments that US customers were charged significantly more for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar expansions have been pledged toward projects in the United States.
A senior figure acknowledged that the NHS had to spend more on drugs, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the past decade.
